EPIVA

Epiva is an immuno-microbiome therapeutics platform. Epiva is the next breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures. As of July 12, 2016, Epiva Biosciences, Inc. was acquired by Evelo Biosciences. Epiva Biosciences, Inc. develops immunobiotic therapeutics, a class of primed bacterial interventions designed to restore normo-biosis, the microbiome signature normally found in healthy people. It focuses on treating conditions characterized by inflammation and aberrant immune responses by modulating the systemic microbiome, the host immune-bacteria interface. The company was founded in 2015 and is based in Cambridge, Massachusetts.